When AstraZeneca PLC delivers its third quarter financials on 24 October, investors will be expecting another strong performance and hoping for positive updates on its promising pipeline as well as three oncology drugs deemed particularly vital to the UK firm's future, those being Lynparza (olaparib), Tagrisso (osimertinib) and Imfinzi (durvalumab).
Also awaited will be updates on AstraZeneca’s mid- and late-stage pipeline, and news on potential additional indications for existing therapies.








